Latest News for: rna interference

Edit

Simcere launches project to tackle neurology, oncology challenges

China Daily 01 Apr 2025
They also include therapeutic applications of RNA interference and mRNA technology in neurodegenerative diseases, cancer and infections, clinical applications of next-generation cell therapies and ...
Edit

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

Pharmiweb 31 Mar 2025
Qfitlia uses small-interfering RNA technology, which enables low treatment ... Qfitlia is a small interference RNA therapeutic that utilizes Alnylam Pharmaceutical Inc.’s ESC-GalNAc conjugate technology.
Edit

RNA Therapies Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, ...

GetNews 17 Mar 2025
"RNA Therapies Clinical Trials" ... RNA therapeutics , ADEL 001, and others ... Novartis holds the global rights to develop, produce, and market LEQVIO through a partnership with Alnylam Pharmaceuticals, a pioneer in RNA interference (RNAi) therapies.
Edit

Idiopathic Pulmonary Fibrosis Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approvals, Therapies, ...

GetNews 14 Mar 2025
announced that it had dosed the first subjects in a Phase I/IIa clinical trial of ARO-MMP7, the company's investigational RNA interference (RNAi) therapeutic designed to reduce the expression of ...
  • 1
×